Engineering and design software provider PTC (NASDAQ:PTC) reported in Q1 CY2025, with sales up 5.5% year on year to $636.4 ...

PTC Therapeutics is poised for a potential turnaround ... patients and limited options for adults create an enormous unmet medical need. The pricing of orphan disease therapies provides insight ...

Golden Lee Scott, Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ: PTCT), recently sold 897 shares of the company’s common stock.The transaction, which ...

In addition, PTC announced that the results of the Phase 3 APHENITY trial were recently published in The Lancet, one of the most prestigious peer-reviewed medical journals. "The Lancet publication ...

“We do work with large global medical device companies and manufacturing companies and stuff like this, where we’re doing PTC but also [adding] our own unique value to that.” “We have that ...

Nearly six months ago, PTC Therapeutics reported positive interim data for a drug in mid-stage development for Huntington’s disease, an inherited neurological disorder with limited treatment ...

PTC Therapeutics Background Information (This ... access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific ...

and medical technology. For more on Codebeamer 3.0, including how it will play an enabling role for Codebeamer AI, read this blog by Christoph Braeuchle, PTC's General Manager of Application ...